Long, Non-coding RNA Gene Expression Signatures to Distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease

Spurlock, Charles F.; John, Tossberg; Guzel, Shaginurova; Andrew, Harmata; Crooke, Philip S.; Thomas, A.G.

doi:10.14309/00000434-201802001-00106

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opinions vary on the classification of IC, as some physicians classify it as a distinct autonomic pathoclinical unit with similar etiology to UC or CD, while others use the IC classification as a temporary diagnosis and rely on additional diagnostic testing over time to establish a diagnosis of CD or UC [61]. Newly developed diagnostic strategies, including novel biochemical assays looking for serum proteins or expression markers derived from peripheral whole blood, could provide additional diagnostic information not only to accurately classify UC and CD, but also to assess disease activity and understand when certain therapies are more or less effective in distinct patient populations [60,62,63].…”

Section: Clinical Manifestation Diagnosis and Management Of Inflmentioning

confidence: 99%

Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes

Wylezinski

Gray

Polk

et al. 2019

JCM

View full text Add to dashboard Cite

Healthcare expenditures in the United States are growing at an alarming level with the Centers for Medicare and Medicaid Services (CMS) projecting that they will reach $5.7 trillion per year by 2026. Inflammatory diseases and related syndromes are growing in prevalence among Western societies. This growing population that affects close to 60 million people in the U.S. places a significant burden on the healthcare system. Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression. Patients require healthcare attention but are initially hidden from clinician’s view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. The current total cost to the U.S. healthcare system is at least $90B dollars annually. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.

show abstract